Markus Berger

8PUBLICATIONS
49CO-AUTHORS
Molecular targetsBiomedical imagingBiomolecular modelling and designBiologically active moleculesChemical engineering design
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 15, 2025
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.

Franziska Siegel, Stephan Siegel, Kristýna Kotýnková

|May 13, 2025
In Vitro and In Vivo Stability Assessment of the Novel, Macrocyclic Gadolinium-Based Contrast Agent Gadoquatrane.

Stephan Gruendemann, Thomas Frenzel, Jessica Lohrke

|Jun 06, 2022
A Novel NAMPT Inhibitor-Based Antibody-Drug Conjugate Payload Class for Cancer Therapy.

Niels Böhnke, Markus Berger, Nils Griebenow

|Aug 24, 2021
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.

Markus Berger, Lars Wortmann, Philipp Buchgraber

|Feb 10, 2018
Discovery of a Novel Oral Glucocorticoid Receptor Modulator (AZD9567) with Improved Side Effect Profile.

Lena Ripa, Karl Edman, Matthew Dearman

|Oct 19, 2017
Isoform-Selective ATAD2 Chemical Probe with Novel Chemical Structure and Unusual Mode of Action.

Amaury E Fernández-Montalván, Markus Berger, Benno Kuropka

Pageof 2

Frequent Collaborators

2 joint publications

Carl Friedrich Nising

2 joint publications

Knut Eis

1 joint publications

Martin Hemmerling

1 joint publications

Anders R Eriksson